Comparative Pharmacology
Head-to-head clinical analysis: ALTOPREV versus KOROSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTOPREV versus KOROSTATIN.
ALTOPREV vs KOROSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.
KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.
Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.
50 mg orally twice daily
None Documented
None Documented
14 hours (terminal); extended-release formulation allows once-daily dosing
8-12 hours in normal renal function; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Renal (10% as active metabolites, 83% as inactive metabolites in urine); fecal (5%)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
HMG-CoA Reductase Inhibitor (Statin)
HMG-CoA Reductase Inhibitor (Statin)